A Phase 1 interventional study of Cannabis in Cannabis Use, Impaired Driving and Cognitive Impairment, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Johns Hopkins University · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 19th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 4 of the 14 other live ones, and was the 28th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 60–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 60+
Johns Hopkins University · Sites in United States
Ages 18–100
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 52 across the 33 interventional studies, 350 across the 1 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
7 of the studies in Cognitive Dysfunction by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05611918Johns Hopkins UniversityREpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study | 2026-12-31 |
| NCT07454824Johns Hopkins Universitye-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most | 2027-02-06 |
| NCT04123314Johns Hopkins UniversityPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | 2027-06-30 |
| NCT06351540Johns Hopkins UniversityExamining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance | 2027-07-01 |
| NCT04765137Johns Hopkins UniversityEvaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
These criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inhaled Cannabis - 0 mg THC
Drug: Cannabis
Inhaled cannabis - 5 mg THC
Drug: Cannabis
Inhaled cannabis - 30 mg THC
Drug: Cannabis
cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Commission Errors
The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Commission errors is measured by calculating the number of trials participants incorrectly push the spacebar in the presence of "X" stimulus.
Time frame: pre-administration, post-administration, 2, 4 hours
Omission Errors
The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Omission errors is measured by calculating the number of trials participants fail to push the spacebar in the presence of a letter that is not an "X" stimulus.
Time frame: pre-administration, post-administration, 2, 4 hours
Reaction Time
The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Reaction time is measured by calculating the duration between the presentation of a letter other than "X", and the correct response of a spacebar push.
Time frame: pre-administration, post-administration, 2, 4 hours
Reaction Time Standard Error
The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Reaction time standard error is measured by calculating the standard error of the mean of the reaction time.
Time frame: pre-administration, post-administration, 2, 4 hours
Visuomotor Index
The visuomotor index score is calculated by mathematically integrating five measures of oculomotor fixation performance and two measures of accuracy into a single score during fixation and accuracy tasks, respectively. Test of visual fixation to measure microsaccades, spontaneous nystagmus, and gaze-evoked nystagmus.
Time frame: pre-administration, post-administration, 2, 4 hours
Saccade Speed
Measures how quickly participants look back and forth between two spots as possible during the oculomotor task.
Time frame: Pre-administration, post-administration, 2, 4 hours
Visually Guided Oculomotor Performance
Measures how quickly and accurately participants move their eyes to a cue as soon as it appears on the oculomotor task.
Time frame: Pre-administration, post-administration, 2, 4 hours
Antisaccade
Measures voluntary eye movement in the direction opposite to the side in which a visual cue is presented.
Time frame: Pre-administration, post-administration, 2, 4 hours
Memory-Guided
Measures how quickly gaze is shifted directly and accurately to a remembered cue position.
Time frame: Pre-administration, post-administration, 2, 4 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.
Of 54 non-industry phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 7 months is below that.
Counting every sponsor, half of 80 studies reached it within 29 months; a quarter within 13 and three quarters within 49.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabis sativa subsp. indica TOP